Genmab A/S (OTCMKTS:GNMSF - Get Free Report) crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $206.48 and traded as high as $211.09. Genmab A/S shares last traded at $211.09, with a volume of 330 shares.
Genmab A/S Stock Down 0.2%
The firm has a market capitalization of $13.95 billion, a P/E ratio of 11.97 and a beta of 0.92. The company's 50 day moving average is $206.48 and its 200-day moving average is $205.86.
Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $3.05 earnings per share for the quarter, beating analysts' consensus estimates of $1.88 by $1.17. Genmab A/S had a net margin of 35.11% and a return on equity of 19.23%. The firm had revenue of $765.14 million for the quarter, compared to analyst estimates of $761.09 million.
Genmab A/S Company Profile
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
